Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 100

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 100
---
 IRS or other taxing authority disagrees with the positions taken on our tax returns, we could have additional tax liability, including interest and penalties. If material, payment of such additional amounts upon final adjudication of any disputes could have a material impact on our business, results of operations, financial condition and growth prospects. Our inability to manage growth could harm our business. In connection with the commercialization of our tests, we have added, and expect to continue to add personnel to certain areas of our business areas including research and development, laboratory operations, quality assurance, compliance, investor relations, reporting, marketing, other financial and legal functions and sales, among others. Further, as we build our commercialization efforts and expand research and development activities for new products and services, and effect potential acquisitions, the scope and complexity of our operations is increasing significantly. As a result of our growth, our operating expenses, our research and development, which includes our Argentine Wet -Laband our product development, and capital requirements will also increase, and we expect that they will continue to increase significantly. We may introduce a hybrid approach to our laboratory operations, with our Argentine Wet -Laband a main laboratory in Mexico; and may send samples to our laboratories or send products for processing to a third party in other countries. As such, our ability to manage our growth effectively requires us to expend funds to improve our operational, financial and management controls, reporting systems and procedures, as well as to achieve scale to allow us to build our own infrastructure. As we move forward in commercializing our tests, we will also need to effectively manage our growing laboratory operations, and sales and marketing needs. We are continuing to expand our current facilities and exploring the need to add new facilities to support anticipated demand for our current and future tests and services. We face various risks in managing these expansion efforts, including financing, development delays, budget management, quality control, design efficiency, and transition execution. If we are unable to execute these growth strategies, including our additional laboratory in Mexico, or manage our anticipated growth effectively, our business could be harmed. Our success depends on the continued emergence and growth of markets for analysis of genetic variation and the ability to generate substantial demand for our tests. The usefulness of our technologies is dependent on the availability of genetic data and its applications in clinical, research, and consumer settings. We are focusing on markets for analysis of genomic variations and omics profiling, using technologies such as sequencing, genotyping, gene expression profiling, deep phenotyping and artificial intelligence. However, these markets are relatively new